Insider Trades102 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 27, 2026 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 67,600 | $16.93 | $1.4B | +0.00% | +174.67% | $1.1M | +0.00% | — | Buy Now |
| May 26, 2026 | Sell | KALV | Nicole Sweeny | Chief Commercial Officer | 1,489 | $26.78 | $1.4B | +0.00% | +174.67% | $39.9K | -1.48% | — | Buy Now |
| May 26, 2026 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 1,966 | $26.78 | $1.4B | +0.00% | +174.67% | $52.6K | -0.77% | — | Buy Now |
| May 26, 2026 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,239 | $26.78 | $1.4B | +0.00% | +174.67% | $60.0K | -1.16% | — | Buy Now |
| May 22, 2026 | Sell | KALV | Brian Piekos | Chief Financial Officer | 1,489 | $26.78 | $1.4B | +0.00% | +174.67% | $39.9K | -1.91% | — | Buy Now |
| May 22, 2026 | Sell | KALV | Nicole Sweeny | Chief Commercial Officer | 1,861 | $26.78 | $1.4B | +0.00% | +174.67% | $49.8K | -1.47% | — | Buy Now |
| May 22, 2026 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 2,358 | $26.78 | $1.4B | +0.00% | +174.67% | $63.2K | -0.87% | — | Buy Now |
| May 22, 2026 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,685 | $26.78 | $1.4B | +0.00% | +174.67% | $71.9K | -1.23% | — | Buy Now |
| May 22, 2026 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 10,926 | $26.78 | $1.4B | +0.00% | +174.67% | $292.6K | -1.46% | — | Buy Now |
| May 18, 2026 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 1,032 | $26.76 | $1.4B | +0.00% | +174.67% | $27.6K | -0.71% | — | Buy Now |
| May 18, 2026 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 1,108 | $26.76 | $1.4B | +0.00% | +174.67% | $29.7K | -0.48% | — | Buy Now |
| May 18, 2026 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 1,129 | $26.76 | $1.4B | +0.00% | +174.67% | $30.2K | -0.24% | — | Buy Now |
| May 12, 2026 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 3,322 | $26.71 | $1.4B | +0.00% | +174.67% | $88.7K | -0.59% | — | Buy Now |
| Apr 17, 2026 | Sell | KALV | Brian Piekos | Chief Financial Officer | 1,862 | $20.22 | $1.4B | +0.00% | +174.67% | $37.6K | -1.64% | — | Buy Now |
| Apr 17, 2026 | Sell | KALV | Nicole Sweeny | Chief Commercial Officer | 1,862 | $20.22 | $1.4B | +0.00% | +174.67% | $37.6K | -1.27% | — | Buy Now |
| Apr 17, 2026 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,686 | $20.22 | $1.4B | +0.00% | +174.67% | $54.3K | -1.12% | — | Buy Now |
| Apr 17, 2026 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 9,550 | $20.22 | $1.4B | +0.00% | +174.67% | $193.1K | -1.23% | — | Buy Now |
| Mar 9, 2026 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 6,693 | $16.08 | $1.4B | +0.00% | +174.67% | $107.6K | -1.15% | — | Buy Now |
| Feb 23, 2026 | Sell | KALV | Brian Piekos | Chief Financial Officer | 1,767 | $15.57 | $1.4B | +0.00% | +174.67% | $27.5K | -2.34% | — | Buy Now |
| Feb 23, 2026 | Sell | KALV | Nicole Sweeny | Chief Commercial Officer | 3,975 | $15.57 | $1.4B | +0.00% | +174.67% | $61.9K | -2.32% | — | Buy Now |
| Feb 23, 2026 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 4,347 | $15.57 | $1.4B | +0.00% | +174.67% | $67.7K | -1.43% | — | Buy Now |
| Feb 23, 2026 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 5,354 | $15.57 | $1.4B | +0.00% | +174.67% | $83.3K | -2.03% | — | Buy Now |
| Feb 23, 2026 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 10,034 | $15.57 | $1.4B | +0.00% | +174.67% | $156.2K | -1.37% | — | Buy Now |
| Feb 18, 2026 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 1,038 | $15.00 | $1.4B | +0.00% | +174.67% | $15.6K | -0.24% | — | Buy Now |
| Feb 18, 2026 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 1,109 | $15.00 | $1.4B | +0.00% | +174.67% | $16.6K | -0.49% | — | Buy Now |
| Feb 18, 2026 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 1,163 | $15.00 | $1.4B | +0.00% | +174.67% | $17.4K | -0.85% | — | Buy Now |
| Feb 12, 2026 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 3,354 | $15.70 | $1.4B | +0.00% | +174.67% | $52.7K | -0.63% | — | Buy Now |
| Dec 8, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 7,294 | $16.51 | $1.4B | +0.00% | +174.67% | $120.4K | -1.27% | — | Buy Now |
| Nov 24, 2025 | Sell | KALV | Nicole Sweeny | Chief Commercial Officer | 3,813 | $13.45 | $1.4B | +0.00% | +174.67% | $51.3K | -2.18% | — | Buy Now |
| Nov 24, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 4,331 | $13.45 | $1.4B | +0.00% | +174.67% | $58.3K | -1.41% | — | Buy Now |
| Nov 24, 2025 | Sell | KALV | Brian Piekos | Chief Financial Officer | 4,471 | $13.45 | $1.4B | +0.00% | +174.67% | $60.1K | -5.59% | — | Buy Now |
| Nov 24, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 5,296 | $13.45 | $1.4B | +0.00% | +174.67% | $71.2K | -1.97% | — | Buy Now |
| Nov 24, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 10,940 | $13.45 | $1.4B | +0.00% | +174.67% | $147.2K | -1.50% | — | Buy Now |
| Nov 20, 2025 | Buy | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 87,390 | $0.00 | $1.4B | +0.00% | +174.67% | $375.777 | +65.42% | — | Buy Now |
| Nov 18, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 2,683 | $14.48 | $1.4B | +0.00% | +174.67% | $38.8K | -1.92% | — | Buy Now |
| Nov 18, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 3,075 | $14.48 | $1.4B | +0.00% | +174.67% | $44.5K | -2.30% | — | Buy Now |
| Nov 18, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 4,466 | $14.48 | $1.4B | +0.00% | +174.67% | $64.7K | -1.08% | — | Buy Now |
| Nov 12, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 3,328 | $11.55 | $1.4B | +0.00% | +174.67% | $38.4K | -0.65% | — | Buy Now |
| Sep 8, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 7,294 | $15.84 | $1.4B | +0.00% | +174.67% | $115.5K | -1.31% | — | Buy Now |
| Aug 25, 2025 | Sell | KALV | Nicole Sweeny | Chief Commercial Officer | 1,480 | $13.42 | $1.4B | +0.00% | +174.67% | $19.9K | -1.67% | — | Buy Now |
| Aug 25, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 1,954 | $13.42 | $1.4B | +0.00% | +174.67% | $26.2K | -1.16% | — | Buy Now |
| Aug 25, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,336 | $13.42 | $1.4B | +0.00% | +174.67% | $31.3K | -1.30% | — | Buy Now |
| Aug 22, 2025 | Sell | KALV | Nicole Sweeny | Chief Commercial Officer | 1,864 | $13.22 | $1.4B | +0.00% | +174.67% | $24.6K | -1.58% | — | Buy Now |
| Aug 22, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 2,362 | $13.22 | $1.4B | +0.00% | +174.67% | $31.2K | -1.27% | — | Buy Now |
| Aug 22, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,942 | $13.22 | $1.4B | +0.00% | +174.67% | $38.9K | -1.40% | — | Buy Now |
| Aug 22, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 10,940 | $13.22 | $1.4B | +0.00% | +174.67% | $144.7K | -1.51% | — | Buy Now |
| Aug 18, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 2,649 | $13.19 | $1.4B | +0.00% | +174.67% | $34.9K | -1.89% | — | Buy Now |
| Aug 18, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,939 | $13.19 | $1.4B | +0.00% | +174.67% | $38.8K | -2.25% | — | Buy Now |
| Aug 18, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 4,409 | $13.19 | $1.4B | +0.00% | +174.67% | $58.1K | -1.12% | — | Buy Now |
| Jul 9, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 30,250 | $15.69 | $1.4B | +0.00% | +174.67% | $474.7K | -19.12% | — | Buy Now |
| Jul 9, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 32,979 | $15.69 | $1.4B | +0.00% | +174.67% | $517.5K | -8.19% | — | Buy Now |
| Jun 9, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 7,169 | $14.50 | $1.4B | +0.00% | +174.67% | $104.0K | -1.45% | — | Buy Now |
| May 23, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 1,926 | $11.31 | $1.4B | +0.00% | +174.67% | $21.8K | -1.40% | — | Buy Now |
| May 23, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,146 | $11.31 | $1.4B | +0.00% | +174.67% | $24.3K | -1.23% | — | Buy Now |
| May 22, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 2,317 | $11.88 | $1.4B | +0.00% | +174.67% | $27.5K | -1.49% | — | Buy Now |
| May 22, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,689 | $11.88 | $1.4B | +0.00% | +174.67% | $31.9K | -1.30% | — | Buy Now |
| May 22, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 9,999 | $11.88 | $1.4B | +0.00% | +174.67% | $118.7K | -1.50% | — | Buy Now |
| May 19, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 2,600 | $11.84 | $1.4B | +0.00% | +174.67% | $30.8K | -2.36% | — | Buy Now |
| May 19, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,776 | $11.84 | $1.4B | +0.00% | +174.67% | $32.9K | -2.18% | — | Buy Now |
| May 19, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 3,808 | $11.84 | $1.4B | +0.00% | +174.67% | $45.1K | -1.19% | — | Buy Now |
| Mar 7, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 6,669 | $11.97 | $1.4B | +0.00% | +174.67% | $79.8K | -1.38% | — | Buy Now |
| Feb 24, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 1,918 | $10.02 | $1.4B | +0.00% | +174.67% | $19.2K | -0.98% | — | Buy Now |
| Feb 24, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,394 | $10.02 | $1.4B | +0.00% | +174.67% | $24.0K | -0.89% | — | Buy Now |
| Feb 18, 2025 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 2,601 | $9.82 | $1.4B | +0.00% | +174.67% | $25.6K | -2.33% | — | Buy Now |
| Feb 18, 2025 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 3,125 | $9.82 | $1.4B | +0.00% | +174.67% | $30.7K | -2.45% | — | Buy Now |
| Feb 18, 2025 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 5,104 | $9.82 | $1.4B | +0.00% | +174.67% | $50.1K | -1.61% | — | Buy Now |
| Dec 9, 2024 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 7,627 | $9.75 | $1.4B | +0.00% | +174.67% | $74.4K | -1.57% | — | Buy Now |
| Nov 26, 2024 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 1,963 | $9.87 | $1.4B | +0.00% | +174.67% | $19.4K | -1.43% | — | Buy Now |
| Nov 26, 2024 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,187 | $9.87 | $1.4B | +0.00% | +174.67% | $21.6K | -1.29% | — | Buy Now |
| Nov 18, 2024 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 7,192 | $9.26 | $1.4B | +0.00% | +174.67% | $66.6K | -6.12% | — | Buy Now |
| Nov 18, 2024 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 8,077 | $9.26 | $1.4B | +0.00% | +174.67% | $74.8K | -6.08% | — | Buy Now |
| Nov 18, 2024 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 14,400 | $9.26 | $1.4B | +0.00% | +174.67% | $133.3K | -4.45% | — | Buy Now |
| Sep 9, 2024 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 7,352 | $12.19 | $1.4B | +0.00% | +174.67% | $89.6K | -1.54% | — | Buy Now |
| Aug 23, 2024 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 1,916 | $12.40 | $1.4B | +0.00% | +174.67% | $23.8K | -1.42% | — | Buy Now |
| Aug 23, 2024 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 2,135 | $12.40 | $1.4B | +0.00% | +174.67% | $26.5K | -1.33% | — | Buy Now |
| Aug 19, 2024 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 7,102 | $12.01 | $1.4B | +0.00% | +174.67% | $85.3K | -5.75% | — | Buy Now |
| Aug 19, 2024 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 7,973 | $12.01 | $1.4B | +0.00% | +174.67% | $95.8K | -5.78% | — | Buy Now |
| Aug 19, 2024 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 14,215 | $12.01 | $1.4B | +0.00% | +174.67% | $170.8K | -4.32% | — | Buy Now |
| Jun 7, 2024 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 7,465 | $11.53 | $1.4B | +0.00% | +174.67% | $86.1K | -1.60% | — | Buy Now |
| May 20, 2024 | Sell | KALV | Edward P. Feener | CHIEF SCIENTIFIC OFFICER | 8,088 | $11.76 | $1.4B | +0.00% | +174.67% | $95.2K | -6.51% | — | Buy Now |
| May 20, 2024 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 11,610 | $11.76 | $1.4B | +0.00% | +174.67% | $136.6K | -8.60% | — | Buy Now |
| May 20, 2024 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 13,175 | $11.76 | $1.4B | +0.00% | +174.67% | $155.0K | -8.71% | — | Buy Now |
| May 20, 2024 | Sell | KALV | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | 21,959 | $11.76 | $1.4B | +0.00% | +174.67% | $258.3K | -6.44% | — | Buy Now |
| Feb 20, 2024 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 12,053 | $14.11 | $1.4B | +0.00% | +174.67% | $170.1K | -7.81% | — | Buy Now |
| Feb 20, 2024 | Sell | KALV | Paul K. Audhya | CHIEF MEDICAL OFFICER | 14,295 | $14.12 | $1.4B | +0.00% | +174.67% | $201.8K | -8.64% | — | Buy Now |
| Feb 20, 2024 | Sell | KALV | Benjamin L Palleiko | CFO, CBO | 22,802 | $14.11 | $1.4B | +0.00% | +174.67% | $321.8K | -6.27% | — | Buy Now |
| Feb 20, 2024 | Sell | KALV | Thomas Andrew Crockett | CEO | 24,888 | $14.11 | $1.4B | +0.00% | +174.67% | $351.3K | -5.92% | — | Buy Now |
| Feb 20, 2024 | Sell | KALV | Edward P. Feener | CHIEF SCIENTIFIC OFFICER | 28,288 | $14.07 | $1.4B | +0.00% | +174.67% | $397.9K | -9.52% | 10b5-1 | Buy Now |
| Feb 14, 2024 | Sell | KALV | Edward P. Feener | CHIEF SCIENTIFIC OFFICER | 28,171 | $15.01 | $1.4B | +0.00% | +174.67% | $422.8K | -28.22% | — | Buy Now |
| Feb 14, 2024 | Sell | KALV | Christopher Yea | CHIEF DEVELOPMENT OFFICER | 39,886 | $15.01 | $1.4B | +0.00% | +174.67% | $598.7K | -37.61% | — | Buy Now |
| Feb 14, 2024 | Sell | KALV | Benjamin L Palleiko | CFO, CBO | 40,855 | $15.01 | $1.4B | +0.00% | +174.67% | $613.2K | -20.43% | — | Buy Now |
| Feb 14, 2024 | Sell | KALV | Thomas Andrew Crockett | CEO | 58,356 | $15.01 | $1.4B | +0.00% | +174.67% | $875.9K | -24.31% | — | Buy Now |
| Feb 1, 2024 | Sell | KALV | Thomas Andrew Crockett | CEO | 10,000 | $16.22 | $1.4B | +0.00% | +174.67% | $162.2K | -4.07% | 10b5-1 | Buy Now |
| Jan 11, 2024 | Sell | KALV | Edward P. Feener | Chief Scientific Officer | 22,679 | $13.03 | $1.4B | +0.00% | +174.67% | $295.5K | -36.28% | 10b5-1 | Buy Now |
| Jan 8, 2024 | Sell | KALV | Edward P. Feener | Chief Scientific Officer | 17,321 | $13.01 | $1.4B | +0.00% | +174.67% | $225.3K | -12.16% | 10b5-1 | Buy Now |
| Dec 27, 2023 | Sell | KALV | Thomas Andrew Crockett | CEO | 30,000 | $12.02 | $1.4B | +0.00% | +174.67% | $360.5K | -19.04% | 10b5-1 | Buy Now |
| Nov 20, 2023 | Sell | KALV | Edward P. Feener | Chief Scientific Officer | 4,958 | $8.23 | $1.4B | +0.00% | +174.67% | $40.8K | -4.07% | — | Buy Now |
| Nov 20, 2023 | Sell | KALV | Christopher Yea | Chief Development Officer | 7,113 | $8.23 | $1.4B | +0.00% | +174.67% | $58.5K | -7.87% | — | Buy Now |
| Nov 20, 2023 | Sell | KALV | Paul K. Audhya | Chief Medical Officer | 7,985 | $8.23 | $1.4B | +0.00% | +174.67% | $65.7K | -7.91% | — | Buy Now |
| Nov 20, 2023 | Sell | KALV | Benjamin L Palleiko | President, CFO, CBO & Sec'y | 13,008 | $8.23 | $1.4B | +0.00% | +174.67% | $107.0K | -6.34% | — | Buy Now |
| Nov 20, 2023 | Sell | KALV | Thomas Andrew Crockett | CEO | 14,807 | $8.23 | $1.4B | +0.00% | +174.67% | $121.9K | -5.18% | — | Buy Now |
| Oct 30, 2023 | Sell | KALV | Thomas Andrew Crockett | CEO | 8,000 | $8.02 | $1.4B | +0.00% | +174.67% | $64.2K | -5.45% | — | Buy Now |